FDA Brief

Warning letters Devices

FDA warning letter to

Peter Schiff Enterprises

High riskIssued Aug 26Posted Oct 27Center for Devices and Radiological Health

FDA warns Peter Schiff Enterprises over unapproved cardiac devices and serious quality system failures.

What happened

FDA inspected the Cookeville, TN firm from December 29-31, 2025. It found the firm marketed cardiac electrode pads (Models 305L and 306L) and an AC cardiac fibrillator (Model 310C) without premarket approval (PMA) or 510(k) clearance and with broad current good manufacturing practice (CGMP) failures. FDA said the firm’s responses were not adequate.

What FDA found

  1. FDA says the cardiac devices are adulterated and misbranded because the firm lacks PMA/510(k) clearance and did not notify FDA before marketing; it also says Model 310C was significantly modified from its preamendments version.

    21 U.S.C. § 351(f)(1), § 352(o); 21 CFR 807.81(a)(3)
  2. FDA found no purchasing control procedure, no supplier quality agreements, and no specifications for materials, including non-medical-grade materials and cleaning agents that contact the devices.

    21 CFR 820.50
  3. FDA found the firm had no design control procedures and did not maintain design history files for the three devices.

    21 CFR 820.30(a)
  4. FDA found complaint handling inadequate: battery-start feedback was not documented as a complaint, and the complaint procedure lacked required elements such as MDR evaluation and investigation records.

    21 CFR 820.198(a)
  5. FDA found nonconforming electrode pads with rust, sunken electrodes, or unsecured wires were not evaluated or dispositioned, and rejected wires were cut and reused without documentation or approval.

    21 CFR 820.90(a)
  6. FDA found no written medical device reporting (MDR) procedures and labels for all three devices lacked a unique device identifier (UDI).

    21 CFR 803.17; 21 CFR 801.20(a)

What FDA wants

FDA asks the firm to correct the cited violations with adequate corrective action plans and timeframes, and recommends submitting a 513(g) request so FDA can formally classify the devices. The letter does not state a response deadline.

Who should pay attention

  • hospitals and cardiac surgery teams
  • distributors and buyers of these devices
  • suppliers of medical-grade materials and components

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  2. Pro-Optics, LLC

    FDA warned Pro-Optics about unapproved material and color changes to contact lens cases and quality system failures.

    Medium
  3. Tides Medical LLC

    FDA warns Tides Medical over APLICOR 3D wound device sold without approval, exemption, or required FDA notice.

    High risk
  4. Specialty Health Products CO, LLC

    Specialty Health Products was cited for quality-system, unapproved marketing, and listing violations for its Hydro-San and Aqua Cleanse colonic irrigation devices.

    High risk